Staci Stevens

Staci R. Stevens, MA in exercise physiology. Founder and Director of Workwell Foundation, Ripon, California, USA. She serves as Co-Vice President of the Board of Directors and Chair of the Membership Committee of the International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. She served a term on the Chronic Fatigue Syndrome Advisory Committee from 2003 - 2006.

Stevens had (in her own words) a very well-controlled case of ME/CFS for greater than 20 years, which motivates her high commitment to advancing understanding of the illness and helping other patients.

Stevens is one of the authors of the 2011 case definition, International Consensus Criteria.

Talks and Interviews

 * 2015, Video: Post-exertional malaise: How to do more with less, Staci Stevens, Vancouver BC Canada, May 2015
 * 2012, MECFS Alert Episode 32: Staci Stevens, Director of the Pacific Fatigue Lab
 * 2012, Top 10 Things You Should Know About Post-Exertional Relapse
 * 2010, Slide presentation to CFSAC
 * 2009, Staci Steven speaking to CFSAC meeting

Notable studies

 * 2013, Discriminative validity of metabolic and workload measurements to identify individuals with Chronic Fatigue Syndrome
 * 2012, A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome."Abstract: 'A Phase III prospective, double-blind, randomized, placebo-controlled trial comparing twice weekly IV rintatolimod versus placebo was conducted in 234 subjects with long-standing, debilitating CFS/ME at 12 sites. The primary endpoint was the intra-patient change from baseline at Week 40 in exercise tolerance (ET). Secondary endpoints included concomitant drug usage, the Karnofsky Performance Score (KPS), Activities of Daily Living (ADL), and Vitality Score (SF 36). Subjects receiving rintatolimod for 40 weeks improved intra-patient placebo-adjusted ET 21.3% (p = 0.047) from baseline in an intention-to-treat analysis. Correction for subjects with reduced dosing compliance increased placebo-adjusted ET improvement to 28% (p = 0.022). The improvement observed represents approximately twice the minimum considered medically significant by regulatory agencies. The rintatolimod cohort vs. placebo also reduced dependence on drugs commonly used by patients in an attempt to alleviate the symptoms of CFS/ME (p = 0.048). Placebo subjects crossed-over to receive rintatolimod demonstrated an intra-patient improvement in ET performance at 24 weeks of 39% (p = 0.04). Rintatolimod at 400 mg twice weekly was generally well-tolerated."
 * 2011, Diagnostic accuracy of symptoms characterising chronic fatigue syndrome
 * 2010, Post-exertional malaise in women with chronic fatigue syndrome
 * 2010, Conceptual model for physical therapist management of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis
 * 2005, Exercise capacity and immune function in male and female patients with Chronic Fatigue Syndrome (CFS)